Trial site
Manhattan Behavioral Medicine PLLC
New York, New York 10036, United StatesNot linked to an institution yet
- 2running trials
- 9closed trials
The trials here
What the 11 trials at this site are about, from their registry records.
- Phase
- Phase 310 trials
- Phase 21 trial
- Status
- Completed6 trials
- Recruiting2 trials
- Terminated2 trials
- Withdrawn1 trial
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.5 trials
- Biohaven Pharmaceuticals, Inc.3 trials
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company2 trials
- Gedeon Richter Plc.1 trial
Closed trials
Completed
A Trial of the Safety and Efficacy of SEP-363856 in the Treatment of Adults With Major Depressive Disorder
NCT05593029· Phase 2· Otsuka Pharmaceutical Development & Commercialization, Inc.· Source
Completed
A Trial of Centanafadine Long-term Safety in Children and Adolescents With Attention-deficit/Hyperactivity Disorder.
NCT05279313· Phase 3· Otsuka Pharmaceutical Development & Commercialization, Inc.· Source
Completed
A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia
NCT05145413· Phase 3· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Source
Completed
An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5)
NCT04820309· Phase 3· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Source
Terminated
Long-term Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder
NCT04708834· Phase 3· Biohaven Pharmaceuticals, Inc.· Source
Completed
A Study to Evaluate the Efficacy and Safety of Adjunctive Troriluzole in Obsessive-Compulsive Disorder
NCT04693351· Phase 3· Biohaven Pharmaceuticals, Inc.· Source
Completed
Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder
NCT04641143· Phase 3· Biohaven Pharmaceuticals, Inc.· Source
Recruiting
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
NCT03817502· Phase 3· Gedeon Richter Plc.· Source
Contact: Balázs Lázár
Terminated
Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
NCT02446132· Phase 3· Otsuka Pharmaceutical Development & Commercialization, Inc.· Source
Report an error